RA'ANANA, Israel, Dec. 4, 2024
/PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd.
(Nasdaq: IINN), (Nasdaq: IINNW) ("Inspira Technologies",
"Inspira" or the "Company"), a groundbreaking life support
technology company, entered into a strategic collaboration with
Westchester Medical Center in Valhalla,
New York. Westchester Medical Center, the flagship hospital
in the Westchester Medical Center Health Network, will evaluate the
performance and effectiveness of the new U.S. Food and Drug
Administration (FDA) cleared INSPIRA ART100 systems in various
real-world clinical scenarios, exposing Inspira's products and
technologies to leading physicians and medical institutions.
The strategic collaboration allows for Westchester Medical
Center, a premier provider of advanced medical care, and Inspira
Technologies, a pioneer of breakthrough technologies, to advance
critical patient care with the deployment of Inspira's proprietary
INSPIRA ART100 systems. The parties have entered the strategic
collaboration with the intention to mutually explore a long-term
collaboration towards the future deployment of Inspira's
next-generation flagship technology, its INSPIRA™ ART system, which
is currently in development and which is being designed to treat
acute respiratory failure by elevating declining oxygen saturation
levels in minutes without mechanical ventilators.
"We are thrilled to supply Westchester Medical Center with our
FDA-cleared INSPIRA ART100 systems," Joe
Hayon, co-founder and President of Inspira Technologies.
"We believe that this collaboration validates the growing interest
in our innovative technology and also provides us with an
opportunity to demonstrate its capabilities in one of New York's premier medical networks."
David Spielvogel, MD, Section
Chief of Cardiothoracic Surgery, Westchester Medical Center,
said: "This partnership exemplifies Westchester Medical
Center's commitment to investing in innovative technologies to
provide the highest, safest, and most effective care. By
integrating this technology we aim to enhance our treatment of
acute respiratory failure and improve patient outcomes. As one of
the few centers in New York State
performing Cardiopulmonary Bypass (CPB) and Extracorporeal Membrane
Oxygenation (ECMO), we are uniquely positioned to leverage this
advanced technology for the benefit of our patients."
About Westchester Medical Center Health Network
The Westchester Medical Center Health Network (WMCHealth)
is a 1,700-bed healthcare system headquartered in Valhalla, New York, with nine hospitals on
seven campuses spanning 6,200 square miles of the Hudson Valley.
WMCHealth employs more than 12,000 people and has nearly 3,000
attending physicians. The Network has Level I (adult and
pediatric), Level II and Level III trauma centers, the region's
only acute care children's hospital, an academic medical center,
several community hospitals, dozens of specialized institutes and
centers, Comprehensive and Primary Stroke Centers, skilled nursing
facilities, home-care services and one of the largest mental health
systems in New York State. Today,
WMCHealth is the pre-eminent provider of integrated health care in
the Hudson Valley. For more information about WMCHealth,
visit WMCHealth.org or follow WMCHealth on
Facebook, Instagram, LinkedIn, YouTube, and X.
About Inspira™ Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company
in the life support and respiratory treatment arena. The Company
has developed a breakthrough Augmented Respiration Technology
(INSPIRA™ ART), a groundbreaking device poised to
revolutionize the $19 billion mechanical ventilation
market. With 20 million intensive care unit patients with acute
respiratory failure each year, many of whom rely on mechanical
ventilators, the INSPIRA ART offers a potential alternative by
elevating and stabilizing decreasing oxygen saturation levels in
minutes without a ventilators, with patient being awake during
treatment. The INSPIRA ART is being equipped with clip-on
HYLA™ blood sensor, a real-time continuous blood monitoring
technology, aiming to alert physicians of changes in a patient's
condition without the need for intermittent actual blood samples,
and potentially supporting physicians in making informed
decisions.
The Company's INSPIRA™ ART100 system has obtained FDA
510(k) clearance for use in Cardiopulmonary Bypass procedures,
along with the Israeli AMAR certification for both Extra-Corporeal
Membrane Oxygenation and Cardiopulmonary Bypass procedures.
The Company's other products and technologies, including the
INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the
INSPIRA™ Cardi-ART portable modular device, VORTX orbiting Oxygen
Delivery System and HYLA™ blood sensor, are currently being
designed and developed, and have not yet been tested or used in
humans and have not been approved by any regulatory entity.
For more information, please visit our corporate
website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the potential of the
collaboration to enable the advancement of critical patient care,
the prospective long-term collaboration in deploying the INSPIRA™
ART System, the belief that this collaboration validates the
growing interest in the Company's innovative technology and
provides the Company with an opportunity to demonstrate its
capabilities in one of New York's
premier medical networks, the belief that this collaboration
exemplifies Westchester Medical Center's commitment to investing in
innovative technologies, that Westchester Medical Center aims to
enhance its treatment of acute respiratory failure and improve
patient outcomes through the integration of this technology and the
belief that Westchester Medical Center is uniquely positioned to
leverage this advanced technology for the benefit of its patients.
These forward-looking statements and their implications are based
solely on the current expectations of the Company's management and
are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements. Except as otherwise required by
law, the Company undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's annual report on Form 20-F for the
fiscal year ended December 31, 2023 filed with the U.S.
Securities and Exchange Commission (the "SEC"), which is available
on the SEC's website, www.sec.gov.
Contact:
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Logo:
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-collaborates-with-new-yorks-westchester-medical-center-to-evaluate-the-inspira-art100-functionality-and-performance-in-clinical-scenarios-302322367.html
SOURCE Inspira Technologies
